CA2445995A1 - Antibacterial agent - Google Patents

Antibacterial agent Download PDF

Info

Publication number
CA2445995A1
CA2445995A1 CA002445995A CA2445995A CA2445995A1 CA 2445995 A1 CA2445995 A1 CA 2445995A1 CA 002445995 A CA002445995 A CA 002445995A CA 2445995 A CA2445995 A CA 2445995A CA 2445995 A1 CA2445995 A1 CA 2445995A1
Authority
CA
Canada
Prior art keywords
amino acids
substances
domain
bacterial
antibacterial agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002445995A
Other languages
English (en)
French (fr)
Inventor
Frank Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novologix GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129870A external-priority patent/DE10129870A1/de
Application filed by Individual filed Critical Individual
Publication of CA2445995A1 publication Critical patent/CA2445995A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002445995A 2001-04-30 2002-04-22 Antibacterial agent Abandoned CA2445995A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10121145 2001-04-30
DE10121145.7 2001-04-30
DE10129870A DE10129870A1 (de) 2001-04-30 2001-06-21 Antibakterielles Mittel
DE10129870.6 2001-06-21
PCT/EP2002/004410 WO2002087554A2 (de) 2001-04-30 2002-04-22 Ef-tu-bindende substanzen als ntibakterielles mittel

Publications (1)

Publication Number Publication Date
CA2445995A1 true CA2445995A1 (en) 2002-11-07

Family

ID=26009202

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002445995A Abandoned CA2445995A1 (en) 2001-04-30 2002-04-22 Antibacterial agent

Country Status (17)

Country Link
EP (1) EP1397157A2 (cs)
JP (1) JP2004534016A (cs)
CN (1) CN1298739C (cs)
AU (1) AU2002302555B2 (cs)
BG (1) BG108399A (cs)
BR (1) BR0209282A (cs)
CA (1) CA2445995A1 (cs)
CZ (1) CZ20033271A3 (cs)
EE (1) EE200300530A (cs)
HU (1) HUP0401586A3 (cs)
IL (1) IL158627A0 (cs)
MX (1) MXPA03009954A (cs)
NZ (1) NZ529662A (cs)
PL (1) PL366836A1 (cs)
RU (1) RU2003134636A (cs)
SK (1) SK14792003A3 (cs)
WO (1) WO2002087554A2 (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229645A1 (de) * 2002-07-02 2004-05-19 Kuchenreuther, Ulrich, Dr. Zellaufschluss von Bakterien
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN105218668B (zh) * 2015-10-30 2020-03-24 山东农业大学 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466251A1 (en) * 1990-07-10 1992-01-15 Gist-Brocades N.V. Elfamycin-resistant mutants
EP1049809B1 (en) * 1998-01-23 2006-10-25 bioMerieux B.V. EF-Tu mRNA AS A MARKER FOR VIABILITY OF BACTERIA
US6451556B1 (en) * 1998-12-21 2002-09-17 Smithkline Beecham Corporation EF-Tu

Also Published As

Publication number Publication date
BR0209282A (pt) 2004-07-27
SK14792003A3 (sk) 2004-07-07
EE200300530A (et) 2004-04-15
HUP0401586A2 (hu) 2004-11-29
HUP0401586A3 (en) 2005-06-28
EP1397157A2 (de) 2004-03-17
BG108399A (bg) 2004-08-31
WO2002087554A2 (de) 2002-11-07
PL366836A1 (en) 2005-02-07
AU2002302555B2 (en) 2007-08-23
RU2003134636A (ru) 2005-04-20
WO2002087554A3 (de) 2003-01-30
WO2002087554B1 (de) 2005-01-27
CN1298739C (zh) 2007-02-07
IL158627A0 (en) 2004-05-12
NZ529662A (en) 2006-08-31
JP2004534016A (ja) 2004-11-11
CZ20033271A3 (en) 2004-06-16
CN1518455A (zh) 2004-08-04
MXPA03009954A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
Vetting et al. Structure and functions of the GNAT superfamily of acetyltransferases
Hansen et al. Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin
KR960705850A (ko) 사람 쿠니즈형 프로테아제 저해인자(human kunitz-type protease inhibitors)
Munk et al. Synthetic analogs of anoplin show improved antimicrobial activities
AU2002302555B2 (en) EF-Tu binding agent as antibacterial agent
Park et al. Role of proline, cysteine and a disulphide bridge in the structure and activity of the anti-microbial peptide gaegurin 5
EP3655421B1 (en) Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof
Sol et al. Actin enables the antimicrobial action of LL-37 peptide in the presence of microbial proteases
Paradis-Bleau et al. Phage display-derived inhibitor of the essential cell wall biosynthesis enzyme MurF
Mukhtar et al. Chimeric streptogramin-tyrocidine antibiotics that overcome streptogramin resistance
US20040198643A1 (en) Antibacterial agent
van Geelen et al. Natural brominated phenoxyphenols kill persistent and biofilm-incorporated cells of MRSA and other pathogenic bacteria
Scioli et al. New Teixobactin Analogues with a Total Lactam Ring
Londei et al. Ribosomes of the extremely thermophilic eubacterium Thermotoga maritima are uniquely insensitive to the miscoding-inducing action of aminoglycoside antibiotics
Tamaki et al. Novel gratisin derivatives with high antimicrobial activity and low hemolytic activity
Zhu et al. Type I and type III collagen–platelet interaction: Inhibition by type specific receptor peptides
Pellegrini et al. Design of synthetic bactericidal peptides derived from the bactericidal domain P18–39 of aprotinin
Giltrap et al. Total synthesis of teixobactin
Nakazawa et al. TNFα induces acetylation of p53 but attenuates its transcriptional activation in rheumatoid synoviocytes
Noden Synthesis and Study of the Cyclic Lipopeptide Antibiotics Paenibacterin and Daptomycin
Ahmed et al. PREPARATION AND CHARACTERISATION OF ANTI-FAT1 POLYCLONAL ANTIBODIES
Hidaka et al. Creation of a Synthetic Ligand for Mitochondrial DNA Sequence Recognition and Promoter-Specific Transcription Suppression
Pirhaghi et al. The anti-platelet drug ticlopidine inhibits FapC fibrillation and biofilm production: Highlighting its antibiotic activity
Parmar Synthesis of Teixobactin Analogues and Their Biological Evaluation
WO1993007892A1 (en) Composition and treatment with biologically active peptides and antibiotic

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued